SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Lucilla Parnetti, Lucia Farotti, Paolo Eusebi, Davide Chiasserini, Claudia De Carlo, David Giannandrea, Nicola Salvadori, Viviana Lisetti, Nicola Tambasco, Aroldo Rossi, Nour K. Majbour, Omar El-Agnaf, Paolo Calabresi, Differential role of CSF alpha-synuclein species, tau, and Aβ42 in Parkinson's Disease, Frontiers in Aging Neuroscience, 2014, 6,

    CrossRef

  2. 2
    Hana Přikrylová Vranová, Eva Hényková, Michaela Kaiserová, Kateřina Menšíková, Miroslav Vaštík, Jan Mareš, Petr Hluštík, Jana Zapletalová, Miroslav Strnad, David Stejskal, Petr Kaňovský, Tau protein, beta-amyloid1–42 and clusterin CSF levels in the differential diagnosis of Parkinsonian syndrome with dementia, Journal of the Neurological Sciences, 2014, 343, 1-2, 120

    CrossRef

  3. 3
    Mona K. Beyer, Guido Alves, Kristy S. Hwang, Sona Babakchanian, Kolbjorn S. Bronnick, Yi-Yu Chou, Turi O. Dalaker, Martin W. Kurz, Jan P. Larsen, Johanne H. Somme, Paul M. Thompson, Ole-Bjørn Tysnes, Liana G. Apostolova, Cerebrospinal fluid Aβ levels correlate with structural brain changes in Parkinson's disease, Movement Disorders, 2013, 28, 3
  4. 4
    Lucilla Parnetti, Anna Castrioto, Davide Chiasserini, Emanuele Persichetti, Nicola Tambasco, Omar El-Agnaf, Paolo Calabresi, Cerebrospinal fluid biomarkers in Parkinson disease, Nature Reviews Neurology, 2013, 9, 3, 131

    CrossRef

  5. 5
    Yaroslau Compta, Joana B. Pereira, Jose Ríos, Naroa Ibarretxe-Bilbao, Carme Junqué, Núria Bargalló, Ana Cámara, Mariateresa Buongiorno, Manel Fernández, Claustre Pont-Sunyer, Maria J. Martí, Combined dementia-risk biomarkers in Parkinson's disease: A prospective longitudinal study, Parkinsonism & Related Disorders, 2013, 19, 8, 717

    CrossRef

  6. 6
    M. Zarei, N. Ibarretxe-Bilbao, Y. Compta, M. Hough, C. Junque, N. Bargallo, E. Tolosa, M. J. Marti, Cortical thinning is associated with disease stages and dementia in Parkinson's disease, Journal of Neurology, Neurosurgery & Psychiatry, 2013, 84, 8, 875

    CrossRef

  7. 7
    Pedro Rosa-Neto, Ging-Yuek Hsiung, Mario Masellis, Fluid biomarkers for diagnosing dementia: rationale and the Canadian Consensus on Diagnosis and Treatment of Dementia recommendations for Canadian physicians, Alzheimer's Research & Therapy, 2013, 5, Suppl 1, S8

    CrossRef

  8. 8
    Swetha Vijayaraghavan, Walter Maetzler, Matthias Reimold, Christina Unger Lithner, Inga Liepelt-Scarfone, Daniela Berg, Taher Darreh-Shori, High apolipoprotein E in cerebrospinal fluid of patients with Lewy body disorders is associated with dementia, Alzheimer's & Dementia, 2013,

    CrossRef

  9. 9
    Jing Zhang, Hayley A. Mattison, Changqin Liu, Carmen Ginghina, Peggy Auinger, Michael P. McDermott, Tessandra Stewart, Un Jung Kang, Kevin C. Cain, Min Shi, Longitudinal assessment of tau and amyloid beta in cerebrospinal fluid of Parkinson disease, Acta Neuropathologica, 2013, 126, 5, 671

    CrossRef

  10. 10
    David J. Irwin, Virginia M.-Y. Lee, John Q. Trojanowski, Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies, Nature Reviews Neuroscience, 2013, 14, 9, 626

    CrossRef

  11. 11
    Yaroslau Compta, Tamas Revesz, Andrew J. Lees, The more cortical amyloid-β, the more postural instability in parkinson's disease: More grist to the mill for a link between walking, falling, and remembering?, Movement Disorders, 2013, 28, 3
  12. 12
    Jing Zhang, Tessandra Stewart, Genomic and Personalized Medicine, 2013,

    CrossRef

  13. 13
    D. Weintraub, N. Dietz, J. E. Duda, D. A. Wolk, J. Doshi, S. X. Xie, C. Davatzikos, C. M. Clark, A. Siderowf, Alzheimer's disease pattern of brain atrophy predicts cognitive decline in Parkinson's disease, Brain, 2012, 135, 1, 170

    CrossRef

  14. 14
    Alessandro Stefani, Livia Brusa, Enrica Olivola, Mariangela Pierantozzi, Alessandro Martorana, CSF and clinical hallmarks of subcortical dementias: focus on DLB and PDD, Journal of Neural Transmission, 2012, 119, 7, 861

    CrossRef

  15. 15
    Kurt A. Jellinger, CSF biomarkers in different phenotypes of Parkinson disease, Journal of Neural Transmission, 2012, 119, 4, 455

    CrossRef

  16. 16
    James F. Morley, Sharon X. Xie, Howard I. Hurtig, Matthew B. Stern, Amy Colcher, Stacy Horn, Nabila Dahodwala, John E. Duda, Daniel Weintraub, Alice S. Chen-Plotkin, Vivianna Van Deerlin, Dana Falcone, Andrew Siderowf, Genetic influences on cognitive decline in Parkinson's disease, Movement Disorders, 2012, 27, 4
  17. 17
    Yaroslau Compta, Naroa Ibarretxe-Bilbao, Joana B. Pereira, Carme Junqué, Núria Bargalló, Eduardo Tolosa, Francesc Valldeoriola, Esteban Muñoz, Ana Camara, Mariateresa Buongiorno, Maria Jose Martí, Grey matter volume correlates of cerebrospinal markers of Alzheimer-pathology in Parkinson's disease and related dementia, Parkinsonism & Related Disorders, 2012, 18, 8, 941

    CrossRef

  18. 18
    Kurt A Jellinger, Neurobiology of cognitive impairment in Parkinson’s disease, Expert Review of Neurotherapeutics, 2012, 12, 12, 1451

    CrossRef

  19. 19
    Rizwan S Akhtar, Matthew B Stern, New concepts in the early and preclinical detection of Parkinson’s disease: therapeutic implications, Expert Review of Neurotherapeutics, 2012, 12, 12, 1429

    CrossRef

  20. 20
    Hana Přikrylová Vranová, Jan Mareš, Petr Hluštík, Martin Nevrlý, David Stejskal, Jana Zapletalová, Radko Obereigneru, Petr Kaňovský, Tau protein and beta-amyloid1-42 CSF levels in different phenotypes of Parkinson’s disease, Journal of Neural Transmission, 2012, 119, 3, 353

    CrossRef

  21. 21
    Kurt A. Jellinger, The role of α-synuclein in neurodegeneration — An update, Translational Neuroscience, 2012, 3, 2, 75

    CrossRef

  22. 22
    Mariateresa Buongiorno, Yaroslau Compta, Maria J. Martí, Amyloid-β and τ biomarkers in Parkinson's disease–dementia, Journal of the Neurological Sciences, 2011, 310, 1-2, 25

    CrossRef

  23. 23
    Min Shi, Joshua Bradner, Aneeka M. Hancock, Kathryn A. Chung, Joseph F. Quinn, Elaine R. Peskind, Douglas Galasko, Joseph Jankovic, Cyrus P. Zabetian, Hojoong M. Kim, James B. Leverenz, Thomas J. Montine, Carmen Ginghina, Un Jung Kang, Kevin C. Cain, Yu Wang, Jan Aasly, David Goldstein, Jing Zhang, Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression, Annals of Neurology, 2011, 69, 3
  24. 24
    M.B. Aerts, R.A.J. Esselink, B.R. Bloem, M.M. Verbeek, Cerebrospinal fluid tau and phosphorylated tau protein are elevated in corticobasal syndrome, Movement Disorders, 2011, 26, 1
  25. 25
    Yu Wang, Aneeka M. Hancock, Joshua Bradner, Kathryn A. Chung, Joseph F. Quinn, Elaine R. Peskind, Douglas Galasko, Joseph Jankovic, Cyrus P. Zabetian, Hojoong M. Kim, James B. Leverenz, Thomas J. Montine, Carmen Ginghina, Karen L. Edwards, Katherine W. Snapinn, David S. Goldstein, Min Shi, Jing Zhang, Complement 3 and Factor H in Human Cerebrospinal Fluid in Parkinson's Disease, Alzheimer's Disease, and Multiple-System Atrophy, The American Journal of Pathology, 2011, 178, 4, 1509

    CrossRef

  26. 26
    Yaroslau Compta, Mario Ezquerra, Esteban Muñoz, Eduardo Tolosa, Francesc Valldeoriola, Jose Rios, Ana Cámara, Manel Fernández, Maria Teresa Buongiorno, Maria Jose Marti, High cerebrospinal tau levels are associated with the rs242557 tau gene variant and low cerebrospinal β-amyloid in Parkinson disease, Neuroscience Letters, 2011, 487, 2, 169

    CrossRef

  27. 27
    David P. Breen, Andrew W. Michell, Roger A. Barker, Parkinson's disease – the continuing search for biomarkers, Clinical Chemistry and Laboratory Medicine, 2011, 49, 3

    CrossRef

  28. 28
    William T. Hu, Alice Chen-Plotkin, Steven E. Arnold, Murray Grossman, Christopher M. Clark, Leslie M. Shaw, Leo McCluskey, Lauren Elman, Jason Karlawish, Howard I. Hurtig, Andrew Siderowf, Virginia M.-Y. Lee, Holly Soares, John Q. Trojanowski, Biomarker discovery for Alzheimer’s disease, frontotemporal lobar degeneration, and Parkinson’s disease, Acta Neuropathologica, 2010, 120, 3, 385

    CrossRef

  29. 29
    Elizabeta B. Mukaetova-Ladinska, Rachael Monteith, Elaine K. Perry, Cerebrospinal Fluid Biomarkers for Dementia with Lewy Bodies, International Journal of Alzheimer's Disease, 2010, 2010, 1

    CrossRef

  30. 30
    Thomas J. Montine, Min Shi, Joseph F. Quinn, Elaine R. Peskind, Suzanne Craft, Carmen Ginghina, Kathryn A. Chung, Hojoong Kim, Douglas R. Galasko, Joseph Jankovic, Cyrus P. Zabetian, James B. Leverenz, Jing Zhang, CSF Aβ42 and tau in Parkinson's disease with cognitive impairment, Movement Disorders, 2010, 25, 15
  31. 31
    Karin D. van Dijk, Charlotte E. Teunissen, Benjamin Drukarch, Connie R. Jimenez, Henk J. Groenewegen, Henk W. Berendse, Wilma D.J. van de Berg, Diagnostic cerebrospinal fluid biomarkers for Parkinson's disease: A pathogenetically based approach, Neurobiology of Disease, 2010, 39, 3, 229

    CrossRef

  32. 32
    G. Stennis Watson, James B. Leverenz, Profile of Cognitive Impairment in Parkinson's Disease, Brain Pathology, 2010, 20, 3
  33. 33
    WonHee Kim, Sangmook Lee, Garth F. Hall, Secretion of human tau fragments resembling CSF-tau in Alzheimer’s disease is modulated by the presence of the exon 2 insert, FEBS Letters, 2010, 584, 14, 3085

    CrossRef

  34. 34
    Kurt A. Jellinger, Parkinson's Disease,